Trial Profile

Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Vorinostat (Primary)
Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Lung cancer; Penile cancer; Squamous cell cancer; Vulvovaginal cancer
Focus Therapeutic Use
Acronyms Basket phase II trial; PEVOsq

Most Recent Events

19 Feb 2025 Status changed from active, no longer recruiting to completed.
01 Feb 2024 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.
24 Oct 2023 Results (n=27) of a sub-group analysis assessing efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com